Compare Crispr Therapeutics AG (CRSP) vs Marathon Digital Holdings Inc (MARA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Marathon Digital Holdings Inc — how do they compare? Crispr Therapeutics AG trades at $50.51 (market cap $4.97B), while Marathon Digital Holdings Inc trades at $11.96 (market cap $4.64B). The key difference: Crispr Therapeutics AG and Marathon Digital Holdings Inc are close in size by market cap, and Marathon Digital Holdings Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | MARA | |
|---|---|---|
Market Cap | $4.97B | $4.64B |
Sector | Health | Technology |
52-Week High | $76.78 | $22.84 |
52-Week Low | $44.34 | $6.73 |
Enterprise Value | $3.32B | $6.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
MARA Holdings trades at $12.19, down 3.25% in the last session. The stock faces bearish technical signals and has missed earnings estimates for three consecutive quarters, with a net income margin of -234.83% in 2025. Recent news highlights the company's strategic pivot to AI infrastructure, including a Texas land acquisition adding 2 GW of power capacity, positioning it for potential growth in high-performance computing.
The outlook is mixed: analyst consensus is a Buy with a $17.88 price target, but significant execution risks exist amid persistent losses and high cash burn. Investors must weigh the AI pivot's long-term potential against near-term financial instability and competitive pressures in the evolving digital infrastructure market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Marathon Digital Holdings Inc
Marathon Digital Holdings, Inc. is one of the largest publicly traded Bitcoin mining companies in North America. The company focuses on building and operating large-scale, cost-efficient Bitcoin mining facilities. Marathon's strategy centers on increasing its mining hash rate and using sustainable energy sources to expand its Bitcoin production. The company's performance is closely tied to the price of Bitcoin and the overall health of the digital asset mining industry.
Read more on MARA →
